We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

48 hedge funds and large institutions have $77.4M invested in Fennec Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

7% more funds holding

Funds holding: 45 → 48 (+3)

0.56% less ownership

Funds ownership: 50.77% → 50.22% (-0.56%)

21% less capital invested

Capital invested by funds: $98.1M → $77.4M (-$20.7M)

Holders
48
Holders Change
+3
Holders Change %
+6.67%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
18
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GIM
Granahan Investment Management
Massachusetts
+$1.54M
2
6CM
683 Capital Management
New York
+$966K
3
OM
Opaleye Management
Massachusetts
+$278K
4
USAA
United Services Automobile Association
Texas
+$250K
5
MAM
Meeder Asset Management
Ohio
+$83.5K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$2.61M
2
JP Morgan Chase
JP Morgan Chase
New York
-$329K
3
CCMINC
Cardinal Capital Management Inc (North Carolina)
North Carolina
-$272K
4
TCIM
TIAA CREF Investment Management
New York
-$62.6K
5
Goldman Sachs
Goldman Sachs
New York
-$60.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFM
26
Hartford Financial Management
Connecticut
$82K -$9.28K -1,000 -9%
MAM
27
Meeder Asset Management
Ohio
$75K +$83.5K +9,004 New
AIG
28
American International Group
New York
$63K +$2.93K +316 +4%
AAMU
29
Amundi Asset Management US
Massachusetts
$56K +$63.1K +6,800 New
Barclays
30
Barclays
United Kingdom
$38K +$35.3K +3,801 +458%
SO
31
STRS Ohio
Ohio
$27K – – –
Citigroup
32
Citigroup
New York
$26K +$14.6K +1,571 +96%
UBS Group
33
UBS Group
Switzerland
$23K -$13.9K -1,494 -35%
JP Morgan Chase
34
JP Morgan Chase
New York
$22K -$329K -35,449 -93%
Bank of America
35
Bank of America
North Carolina
$19K +$6.3K +679 +44%
Legal & General Group
36
Legal & General Group
United Kingdom
$14K – – –
Wells Fargo
37
Wells Fargo
California
$14K +$3.67K +396 +29%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$8K +$8.06K +869 +1,259%
AIP
39
Ameritas Investment Partners
Nebraska
$7K – – –
EWM
40
Edge Wealth Management
New York
$4K – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$3.03K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$3K +$2.88K +311 New
Bank of Montreal
43
Bank of Montreal
Ontario, Canada
$1K -$9 -1 -1%
Toronto Dominion Bank
44
Toronto Dominion Bank
Ontario, Canada
$1K +$501 +54 +235%
FHB
45
First Hawaiian Bank
Hawaii
$1K +$789 +85 New
WSTAM
46
Wilbanks Smith & Thomas Asset Management
Virginia
$1K +$928 +100 New
FDCDDQ
47
Federation des caisses Desjardins du Quebec
Quebec, Canada
$8 – – –
ACP
48
Acuta Capital Partners
California
– -$2.61M -250,000 Closed
CCMINC
49
Cardinal Capital Management Inc (North Carolina)
North Carolina
– -$272K -26,047 Closed
PIA
50
Piedmont Investment Advisors
North Carolina
– -$2K -197 Closed
1
2
3

FENC Hedge Fund Activity: Q3 2018 in Review

48 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2018, worth a combined $77.4M — down 21% from $98.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new FENC positions and 3 closed out — a net gain of 3 holders — while 18 added to existing stakes and 9 trimmed.

The largest buyer was Granahan Investment Management, adding an estimated $1.54M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $2.61M sold.

  • 48 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2018, up from 45 in Q2 2018.
  • Funds reported $77.4M of Fennec Pharmaceuticals stock for Q3 2018, down 21% quarter-over-quarter.
  • 6 funds opened new Fennec Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +3 holders.
  • The largest Fennec Pharmaceuticals buyer in Q3 2018 was Granahan Investment Management, an estimated $1.54M added.
  • The largest Fennec Pharmaceuticals seller in Q3 2018 was Acuta Capital Partners, an estimated $2.61M sold.

Based on aggregated 13F filings for Q3 2018.